Chinese Academy of Sciences (CAS) Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
School of Biomedical Sciences, The University of Hong Kong, Hong Kong, Hong Kong, SAR China.
Front Immunol. 2021 Oct 20;12:730116. doi: 10.3389/fimmu.2021.730116. eCollection 2021.
found in the normal flora of the human oral and intestinal tract mainly causes hospital-acquired infections but can also cause community-acquired infections. To date, most clinical trials of vaccines against have ended in failure. Furthermore, no single conserved protein has been identified as an antigen candidate to accelerate vaccine development. In this study, we identified five outer membrane proteins of , namely, Kpn_Omp001, Kpn_Omp002, Kpn_Omp003, Kpn_Omp004, and Kpn_Omp005, by using reliable second-generation proteomics and bioinformatics. Mice vaccinated with these five KOMPs elicited significantly higher antigen-specific IgG, IgG1, and IgG2a. However, only Kpn_Omp001, Kpn_Omp002, and Kpn_Omp005 were able to induce a protective immune response with two infection models. These protective effects were accompanied by the involvement of different immune responses induced by KOMPs, which included KOMPs-specific IFN-γ-, IL4-, and IL17A-mediated immune responses. These findings indicate that Kpn_Omp001, Kpn_Omp002, and Kpn_Omp005 are three potential Th1, Th2, and Th17 candidate antigens, which could be developed into multivalent and serotype-independent vaccines against infection.
在人类口腔和肠道的正常菌群中发现,主要引起医院获得性感染,但也可引起社区获得性感染。迄今为止,针对的大多数临床疫苗试验都以失败告终。此外,尚未确定任何单一的保守蛋白作为抗原候选物来加速疫苗的开发。在这项研究中,我们使用可靠的第二代蛋白质组学和生物信息学技术鉴定了 5 种外膜蛋白,即 Kpn_Omp001、Kpn_Omp002、Kpn_Omp003、Kpn_Omp004 和 Kpn_Omp005。用这些 5 种 KOMPs 免疫的小鼠引发了明显更高的抗原特异性 IgG、IgG1 和 IgG2a。然而,只有 Kpn_Omp001、Kpn_Omp002 和 Kpn_Omp005 能够在两种 感染模型中诱导出保护性免疫反应。这些保护作用伴随着由 KOMPs 诱导的不同免疫反应的参与,包括 KOMPs 特异性 IFN-γ-、IL4-和 IL17A 介导的免疫反应。这些发现表明 Kpn_Omp001、Kpn_Omp002 和 Kpn_Omp005 是三种潜在的 Th1、Th2 和 Th17 候选抗原,可开发成针对 感染的多价和血清型非依赖性疫苗。